#ASH25: AstraZeneca’s dual-targeting CAR-T sees similar responses in Western patients as in Chinanews2025-12-06T20:00:15+00:00December 6th, 2025|Endpoints News|
#ASH25: As one door closes for Regeneron’s lymphoma bispecific, another reopensnews2025-12-06T14:30:29+00:00December 6th, 2025|Endpoints News|
ORIC’s lung cancer pill shows promise in some settings but is dropped for HER2 mutationsnews2025-12-06T01:00:15+00:00December 6th, 2025|Endpoints News|
Rapport shares updated results from Phase 2 study of seizure drugnews2025-12-05T16:02:46+00:00December 5th, 2025|Endpoints News|
Praxis stops pivotal trial of rare epilepsy drug early for efficacynews2025-12-05T11:10:58+00:00December 5th, 2025|Endpoints News|
ACIP delays vote on hepatitis B birth dose to Fridaynews2025-12-04T20:51:19+00:00December 4th, 2025|Endpoints News|
With Phase 3 Duchenne success, Capricor plots path forward after FDA rejectionnews2025-12-03T16:36:07+00:00December 3rd, 2025|Endpoints News|
Black Diamond reports mid-stage lung cancer data, continues its hunt for a partnernews2025-12-03T16:35:49+00:00December 3rd, 2025|Endpoints News|
Bristol Myers pushes back Cobenfy readout after trial site ‘irregularities’news2025-12-03T12:41:17+00:00December 3rd, 2025|Endpoints News|
Updated: Pharvaris’ hereditary angioedema drug gets Phase 3 winnews2025-12-03T12:20:48+00:00December 3rd, 2025|Endpoints News|
